Drenth JPH

ORCID: 0000-0001-8027-3073 · 4 papers in corpus
2025
Hepatic Safety Considerations in the Use of Ulipristal Acetate for Symptomatic Uterine Fibroids.
Therapeutics and clinical risk management ·doi:10.2147/tcrm.s273358

IntroductionUlipristal acetate (UPA, 5 mg) demonstrated efficacy in symptom reduction for patients with symptomatic fibroids. While registration and post-marketing trials assessing UPA identified few hepatic concerns, post-marketing concern…

2022
Protocol for a randomized controlled multicenter trial assessing the efficacy of leuprorelin for severe polycystic liver disease: the AGAINST-PLD study.
BMC gastroenterology ·doi:10.1186/s12876-022-02142-y

BackgroundIn patients with severe polycystic liver disease (PLD), there is a need for new treatments. Estrogens and possibly other female sex hormones stimulate growth in PLD. In some patients, liver volume decreases after menopause. Female…

2008
Chymotrypsin C (CTRC) variants that diminish activity or secretion are associated with chronic pancreatitis.
Nature genetics ·doi:10.1038/ng.2007.44

Chronic pancreatitis is a persistent inflammatory disease of the pancreas, in which the digestive protease trypsin has a fundamental pathogenetic role. Here we have analyzed the gene encoding the trypsin-degrading enzyme chymotrypsin C (CTR…

2006
A degradation-sensitive anionic trypsinogen (PRSS2) variant protects against chronic pancreatitis.
Nature genetics ·doi:10.1038/ng1797

Chronic pancreatitis is a common inflammatory disease of the pancreas. Mutations in the genes encoding cationic trypsinogen (PRSS1) and the pancreatic secretory trypsin inhibitor (SPINK1) are associated with chronic pancreatitis. Because in…